Literature DB >> 21150330

Alternative activation of tumor-associated macrophages by IL-4: priming for protumoral functions.

Hao-Wei Wang1, Johanna A Joyce.   

Abstract

Although macrophages were originally recognized as major immune effector cells, it is now appreciated that they also play many important roles in the maintenance of tissue homeostasis, and are involved in a variety of pathological conditions including cancer. Several studies have demonstrated the contributions of tumor-associated macrophages (TAMs) to tumor initiation, progression, and metastasis. However, the detailed mechanisms underlying how TAMs differ molecularly from their normal counterparts and how the conversion to TAMs occurs have only just begun to be understood. TAMs have been proposed to exhibit phenotypes of 'alternatively activated' macrophages, though there has been limited evidence directly linking the phenotypes of TAMs to the alternative activation of macrophages. This review will focus on IL-4, the prototypic cytokine that induces the alternative activation of macrophages, and review current knowledge regarding the contributions of IL-4 to the phenotypes of TAMs and its effects on tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21150330      PMCID: PMC3047808          DOI: 10.4161/cc.9.24.14322

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  141 in total

Review 1.  Multinucleated giant cells.

Authors:  J M Anderson
Journal:  Curr Opin Hematol       Date:  2000-01       Impact factor: 3.284

Review 2.  Chemokines: immunology's high impact factors.

Authors:  C R Mackay
Journal:  Nat Immunol       Date:  2001-02       Impact factor: 25.606

Review 3.  IL-4/IL-13 signaling beyond JAK/STAT.

Authors:  H Jiang; M B Harris; P Rothman
Journal:  J Allergy Clin Immunol       Date:  2000-06       Impact factor: 10.793

4.  M-1/M-2 macrophages and the Th1/Th2 paradigm.

Authors:  C D Mills; K Kincaid; J M Alt; M J Heilman; A M Hill
Journal:  J Immunol       Date:  2000-06-15       Impact factor: 5.422

5.  IFN-gamma and IL-4 differently regulate inducible NO synthase gene expression through IRF-1 modulation.

Authors:  E M Coccia; E Stellacci; G Marziali; G Weiss; A Battistini
Journal:  Int Immunol       Date:  2000-07       Impact factor: 4.823

6.  Cutting edge: STAT6-deficient mice have enhanced tumor immunity to primary and metastatic mammary carcinoma.

Authors:  S Ostrand-Rosenberg; M J Grusby; V K Clements
Journal:  J Immunol       Date:  2000-12-01       Impact factor: 5.422

7.  Cutting edge: spontaneous rejection of poorly immunogenic P1.HTR tumors by Stat6-deficient mice.

Authors:  A K Kacha; F Fallarino; M A Markiewicz; T F Gajewski
Journal:  J Immunol       Date:  2000-12-01       Impact factor: 5.422

8.  The activity of soluble VCAM-1 in angiogenesis stimulated by IL-4 and IL-13.

Authors:  J Fukushi; M Ono; W Morikawa; Y Iwamoto; M Kuwano
Journal:  J Immunol       Date:  2000-09-01       Impact factor: 5.422

Review 9.  The molecular basis of macrophage fusion.

Authors:  Laura Helming; Siamon Gordon
Journal:  Immunobiology       Date:  2007-11-09       Impact factor: 3.144

10.  Human breast carcinoma cells express type II IL-4 receptors and are sensitive to antitumor activity of a chimeric IL-4-Pseudomonas exotoxin fusion protein in vitro and in vivo.

Authors:  P Leland; J Taguchi; S R Husain; R J Kreitman; I Pastan; R K Puri
Journal:  Mol Med       Date:  2000-03       Impact factor: 6.376

View more
  64 in total

Review 1.  Microenvironmental regulation of tumor progression and metastasis.

Authors:  Daniela F Quail; Johanna A Joyce
Journal:  Nat Med       Date:  2013-11       Impact factor: 53.440

Review 2.  Progress in tumor-associated macrophage (TAM)-targeted therapeutics.

Authors:  Chayanon Ngambenjawong; Heather H Gustafson; Suzie H Pun
Journal:  Adv Drug Deliv Rev       Date:  2017-04-25       Impact factor: 15.470

3.  Excitatory pathway engaging glutamate, calcineurin, and NFAT upregulates IL-4 in ischemic neurons to polarize microglia.

Authors:  Shun-Ming Ting; Xiurong Zhao; Xueping Zheng; Jaroslaw Aronowski
Journal:  J Cereb Blood Flow Metab       Date:  2019-03-19       Impact factor: 6.200

Review 4.  Tumor-associated macrophages: Role in the pathological process of tumorigenesis and prospective therapeutic use (Review).

Authors:  Olga V Zhukova; Tatiana F Kovaleva; Evgenia V Arkhipova; Sergey A Ryabov; Irina V Mukhina
Journal:  Biomed Rep       Date:  2020-08-28

Review 5.  Targeting IL4/IL4R for the treatment of epithelial cancer metastasis.

Authors:  Katherine Venmar Bankaitis; Barbara Fingleton
Journal:  Clin Exp Metastasis       Date:  2015-09-18       Impact factor: 5.150

6.  The cellular and molecular origin of tumor-associated macrophages.

Authors:  Ruth A Franklin; Will Liao; Abira Sarkar; Myoungjoo V Kim; Michael R Bivona; Kang Liu; Eric G Pamer; Ming O Li
Journal:  Science       Date:  2014-05-08       Impact factor: 47.728

Review 7.  Cytokine stimulation of epithelial cancer cells: the similar and divergent functions of IL-4 and IL-13.

Authors:  Miranda A Hallett; Katherine T Venmar; Barbara Fingleton
Journal:  Cancer Res       Date:  2012-12-07       Impact factor: 12.701

Review 8.  The gastrointestinal tumor microenvironment.

Authors:  Michael Quante; Julia Varga; Timothy C Wang; Florian R Greten
Journal:  Gastroenterology       Date:  2013-04-10       Impact factor: 22.682

9.  STAT3 and STAT6 Signaling Pathways Synergize to Promote Cathepsin Secretion from Macrophages via IRE1α Activation.

Authors:  Dongyao Yan; Hao-Wei Wang; Robert L Bowman; Johanna A Joyce
Journal:  Cell Rep       Date:  2016-09-13       Impact factor: 9.423

Review 10.  The tumor microenvironment: An irreplaceable element of tumor budding and epithelial-mesenchymal transition-mediated cancer metastasis.

Authors:  Hui Li; Fangying Xu; Si Li; Anjing Zhong; Xianwen Meng; Maode Lai
Journal:  Cell Adh Migr       Date:  2016-01-08       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.